Biomarker-guided selection of intravesical therapy in high-risk non–muscle invasive bladder cancer: A contemporary review
High-risk non–muscle invasive bladder cancer poses therapeutic challenges, with significant rates of recurrence and progression with standard intravesical bacillus Calmette-Guérin (BCG) therapy. Current surveillance strategies lack accurate risk stratification models to predict individual treatment response and persona...